Business
Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors
New ADAPTIR Candidate APVO603 is a Dual-Agonistic BispecificAntibody Targeting 4-1BB and OX40 APVO603 is Designed to Induce Synergistic Effects on Immune
About this update from Aptevo Therapeutics Inc.
[{"type":"text","content":"New ADAPTIR Candidate APVO603 is a Dual-Agonistic BispecificAntibody Targeting 4-1BB and OX40\n APVO603 is Designed to Induce Synergistic Effects on Immune Responseswith Potential to Enhance Anti-Tumor Immune Response Against Solid Tumors SEATTLE, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today introduced a new immuno-oncology candidate, APVO603, built on Aptevo’s proprietary ADAPTIR™ bispecific antibody platform. Dr. Jane Gross, Chief Scientific Officer for Aptevo, will present preclinical data on APVO603 in an oral presentation today at the 10th Annual World Bispecific Summit in Waltham, MA. APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family. Dual targeting of 4-1BB and OX40 provides synergistic co-stimulation of T cells with the potential to amplify the cytotoxic function of activated T cells and NK cells, potentially leading to more robust anti-tumor responses. “Aptevo continues to create new, innovative molecules based on our ADAPTIR platform technology and we are excited to introduce our newest bispecific antibody candidate, APVO603,” said Jane Gross, Ph.D., Chief Scientific Officer for Aptevo. “APVO603 demonstrates the versatility and flexibility of our ADAPTIR platform to generate multiple candidates with diverse mechanisms of action (T-cell engagers, T-cell co-stimulators and targeted cytokines) for the treatment of cancer and autoimmune diseases. Importantly, this flexibility allows us to engineer novel molecules addressing both hematological cancers and solid tumors – a significant area of unmet medical need within the field of immuno-oncology therapeutics.” “We believe that a targeted strategy combining activation of both the 4-1BB and OX40 TNF receptors represents an attractive approach in potentially overcoming the suppressive tumor microenvironment,” continued Dr. Gross. “The targeted co-stimulation of 4-1BB and OX40 has the potential to promote an important immunological cascade, enhancing T-cell activation, prolonging T-cell survival, and improving tumor killing. We look forward to furthering our preclinical work and advancing APVO603 towards clinical...